Focus: Medivation tug-of-war rumbles on
May 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, Medivation, Pfizer, Sanofi, billion dollar, competition, oncology, pipeline, promising, takeover, tug of war
Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line up, all vying to secure …
Merck & Co Q1 sales hurt by generics, currency impact
May 6, 2016Medical Communications, Sales and Marketing Financial, Merck & Co, Q1, Revenye, earnings, results, sales
US pharma major Merck & Co (NYSE: MRK) posted a drop in first-quarter sales impacted the launch of generic competition …
Valeant announces new patient access and pricing committee; vows to correct past “mistakes”
May 6, 2016Medical Communications, Sales and Marketing Valeant, joseph papa, new committee, patient access, price gouging, pricing
Valeant (NYSE: VRX) has announced the establishment of a new patient access and pricing committee that will be responsible for …
Pfizer teams up with Wave Life Sciences for metabolic disease research
May 6, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pfizer, metabolic disease, nucelic acid therapies, partnership, wave life sciences
Pfizer (NYSE: PFE) has entered into a research, license and option agreement with Wave Life Sciences (NASDAQ: WVE) for the …
Amgen looking to join the fray, mulling Medivation bid – Reports
May 5, 2016Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …
Valeant’s Bausch + Lomb teams up with IBM for cataract surgery app
May 5, 2016Research and Development Bausch and Lomb, Valeant, app, cataract, cataract surgery, ibm, ipad, iphone, surgeons
IBM (NYSE: IBM) and Bausch + Lomb, a wholly owned subsidiary of Valeant (NYSE: VRX), have announced a partnership that …
Sanofi sends letter to Medivation board; claims shareholders want takeover
May 5, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Medivation, Sanofi, board, brandicourt, hostile, shareholders, takeover
The CEO of Sanofi has issued a strongly worded letter to the board at Medivation, indicating that shareholders support their …
Eisai says European Commission backs Halaven to treat of advanced Liposarcoma in Europe
May 5, 2016Research and Development, Sales and Marketing EC, Eisai, US FDA, oncology, regulation, soft tissue sarcoma
The European Commission has backed marketing for the Japanese drug major Eisai’s (TYO: 4523) Halaven (eribulin) to treat advanced soft …
One in three antibiotic prescriptions in US unnecessary, says CDC
May 5, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDC, antibiotic, prescribing, prescriptions, unnecessary
Approximately 30% of all prescriptions of antibiotics in the United States are unnecessary, according to new data published by the …
Eli Lilly’s cancer drug candidate scores FDA priority review
May 5, 2016Eli Lilly, US FDA, oncology, regulation
US drugmaker Eli Lilly (NYSE: LLY) said the US Food and Drug Administration (FDA) has granted priority review for its …
Bayer’s liver cancer drug meets primary endpoint in late stage trial
May 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial
Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …
Biogen to spin off its haemophilia business
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing Biogen, Business, alprolix, eloctate, haemophilia, hemophilia, spin off, spin-off
Biogen (NASDAQ: BIIB) has announced plans to spin off its haemophilia business as an independent, publicly traded company. To be …
Nice extends price-negotiation talks for PTC’ muscle wasting drug
May 4, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, NICE, PTC Therapeutics, Translarna, market access, regulation
UK regulators have extended the cost negotiation talks with PTC Therapeutics (Nasdaq: PTCT) by a week for the drug to …
Pfizer revenue jumps 20%; ups FY16 outlook
May 4, 2016Research and Development, Sales and Marketing Pfizer, Q1, earnings, results, revenue, sales
US pharma giant Pfizer (NYSE: PFE) reported a 20% jump in first-quarter revenue boosted by performance of its new cancer …
Sun Pharma to partner with ICGEB to develop novel Dengue treatment
May 4, 2016Research and Development Dengue fever, Sun Pharma, collaboration, dengue, development, drug, icgeb, international centre for genetic engineering and biotechnology, partnership, sun pharmaceutical
Sun Pharmaceuticals (BSE: 85715) and the International Centre for Genetic Engineering and Biotechnology (ICGEB) are set to team up to …
US biotech company to try resurrect the clinically dead
May 4, 2016Research and Development US, bioquark, biotech, brain, central nervous system, clinically dead, dead, patients, ressurect
A US biotech firm has announced plans for a Phase I trial that will see them attempt to bring brain-dead …
Pfizer joins the race, bids for Medivation – Reports
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …
FDA grants priority review for Amgen leukaemia drug
May 4, 2016Research and Development, Sales and Marketing Amgen, FDA, blincyto, leukaemia, lymphoblastic leukaemia, paediatric
Amgen has announced that the US Food and Drug Administration (FDA) has granted priority review status for the supplemental Biologics …
Quintiles to merge with IMS Health
May 3, 2016Medical Communications, Research and Development, Sales and Marketing IMS Health, Quintiles, merger
IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement has been made between the …
New CFO at Mylan
May 3, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, cfo, kenneth parks
Mylan has announced the appointment of Kenneth S. Parks as its new chief financial officer, effective June 6 2016. Parks …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
